Skip to main content

FDA Approvals

Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer

Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form

FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants

Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia

FDA Approvals, Infectious Diseases

FDA Approved Abrysvo, First RSV Vaccine for Immunizing Pregnant Women, as Prophylaxis Against RSV Infection in Infants

FDA Approvals, Multiple Sclerosis

Tyruko First Biosimilar for the Treatment of Relapsing Forms of Multiple Sclerosis

FDA Approved Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma

Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program

Ojjaara FDA Approved for Treatment of Myelofibrosis and Anemia

Exxua, a First-in-Class Oral Selective 5-HT1A Receptor Agonist, FDA Approved for Major Depressive Disorder

Page 3 of 53
Results 21 - 30 of 524